Abstract: The purpose of the present invention is to provide a pre-filled syringe formulation with staked needle, which contains an antibody at a high concentration and can be produced on an industrial scale in a simple manner without causing clogging. A pre-filled syringe formulation with staked needle, in which a protein solution is packed. The pre-filled syringe formulation is characterized in that a cap formed with a material having low water vapor permeability is provided at the needle.

Abstract: The purpose of the present invention is to provide a pre-filled syringe formulation with staked needle, which contains an antibody at a high concentration and can be produced on an industrial scale in a simple manner without causing clogging. A pre-filled syringe formulation with staked needle, in which a protein solution is packed. The pre-filled syringe formulation is characterized in that a cap formed with a material having low water vapor permeability is provided at the needle.

Abstract: A crosslinking reaction and a reaction for reducing molecular weight that take place in a hyaluronic acid-methotrexate conjugate upon irradiation with light are suppressed to improve the photostability of the conjugate. Specifically, a substance having a quenching effect and/or a radical scaveng effect is added to a pharmaceutical composition containing the hyaluronic acid-methotrexate conjugate.

Abstract: The present invention provides stabilized preparations containing an antibody in a glycine buffer and/or a histidine buffer and also provides processes for preparing a protein-containing stabilized preparation, comprising adjusting the pH with a basic amino acid or a basic amino acid derivative or a salt thereof.

Abstract: A crosslinking reaction and a reaction for reducing molecular weight that take place in a hyaluronic acid-methotrexate conjugate upon irradiation with light are suppressed to improve the photostability of the conjugate. Specifically, a substance having a quenching effect and/or a radical scaveng effect is added to a pharmaceutical composition containing the hyaluronic acid-methotrexate conjugate.

Abstract: A stabilized antibody-containing preparation containing acetyltryptophan or an acetyltryptophan derivative or a salt thereof as a stabilizer for controlling the decrease in the biological activity of the antibody.

Abstract: A stable protein formulation containing tryptophan or a tryptophan derivative or a salt thereof as a stabilizer.

Abstract: This invention provides an erythropoietin solution preparation containing an amino acid as a stabilizer, and having excellent long-term storage stability.

Abstract: A stabilized antibody-containing preparation containing acetyltryptophan or an acetyltryptophan derivative or a salt thereof as a stabilizer for controlling the decrease in the biological activity of the antibody.

Abstract: This invention provides an erythropoietin solution preparation containing an amino acid as a stabilizer, and having excellent long-term storage stability.

Abstract: The present invention provides stabilized preparations containing an antibody in a glycine buffer and/or a histidine buffer and also provides processes for preparing a protein-containing stabilized preparation, comprising adjusting the pH with a basic amino acid or a basic amino acid derivative or a salt thereof.

Abstract: This invention provides an erythropoietin solution preparation containing an amino acid as a stabilizer, and having excellent long-term storage stability.

Abstract: A stabilized pharmaceutical preparation of an antibody to parathyroid hormone related peptide, wherein the antibody is dissolved in a buffer solution containing at least one buffer selected from the group consisting of acetic acid, citric acid, phosphoric acid, and salts thereof and is in the form of a solution of pH 5 to 8.

Abstract: A stable protein formulation containing tryptophan or a tryptophan derivative or a salt thereof as a stabilizer.

Abstract: This invention provides an erythropoietin solution preparation containing an amino acid as a stabilizer, and having excellent long-term storage stability.

Abstract: This invention provides an erythropoietin solution preparation containing an amino acid as a stabilizer, and having excellent long-term storage stability.

Abstract: This invention provides an erythropoietin solution preparation containing an amino acid as a stabilizer, and having excellent long-term storage stability.

Abstract: DL-leupeptins have been known to be produced by leupeptins-producing organisms and only L-leupeptins have bioactivity. This invention provides the processes for production of L-leupeptins in high yield and for its extraction without racemization.L-leupeptins may be efficiently produced by inoculating a leupeptins-producing strain of Streptomyces into a medium containing nutrient sources and aerobically cultivating under the condition of pH 5.0 to 7.0. Production of L-leupeptins is markedly increased by adding to the medium each 0.5 to 1.25% (wt/vol) of L-leucine, L-arginine (as hydrochloride), and glycine, and is further increased by adding to the medium 0.05 to 0.3% (wt/vol) of at least one of the yeast extract, casein hydrolyzate, and ribonucleic acids, in addition to the above amino acids. Efficient separation of L-leupeptins of acceptable purity from the cultured broth can be effected by use of a nonionic adsorbent resin, wherein the pH is controlled always to be 7.0 or lower.